Study of Inflammatory Mechanisms in Epidermolysis Bullosa Simplex- Dowling Meara
Introduction: Epidermolysis Bullosa Simplex-Dowling-Meara (DM-EBS) is a rare genodermatosis characterized by spontaneous or post traumatic large cutaneous blisters. No curative treatment is actually available. Some data suggest a role of inflammation in the occurrence of blisters. The aim of this study is to study the epidermis inflammatory mechanisms in DM-EBS.
Material and methods: A first retrospective immunohistochemical study will be led on remainder skin biopsies of DM-EBS patients took for the diagnosis. A second clinical multicentric prospective study will be led on 8 patients older than 1 year with severe DM-EBS. After informed written consent, they will answer to a standardized questionnaire. In case of flare of the disease, the liquid and the top of the blisters will be took. Samples will be analyzed in the Pr Nicolas 851 INSERM unit. After centrifugation of the liquid blisters, the repartition of inflammatory cells will be evaluated by Fluorescence Activated Cell Sorting on the pellet. Markers of inflammation will be evaluated on the surnageant with Luminex® technical with a multiplex targeting cytokines and chemokines. An immuno-histochemic analysis in association with a quantitative PCR will be made on the top of the blisters. If unknown, genotypic study will be made.
Perspectives: A better comprehension of physiopathological mechanisms in DM-EBS could offer new therapeutic ways.
|Epidermolysis Bullosa Simplex Dowling Meara||Procedure: Taking of liquid and top of blisters|
|Study Design:||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
|Official Title:||Study of Inflammatory Mechanisms in Epidermolysis Bullosa Simplex- Dowling Meara|
- Markers of inflammation in epidermis in patients with severe DM-BS [ Time Frame: Baseline ]
- clinical characterization of DM-EBS Genotype-phenoty [ Time Frame: Baseline ]
|Study Start Date:||March 2012|
|Study Completion Date:||October 2013|
|Primary Completion Date:||March 2012 (Final data collection date for primary outcome measure)|
Procedure: Taking of liquid and top of blisters
the liquid and the top of blisters will be took.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01556308
|Hôpital Archet 2|
|Nice, France, 06200|